Skip to content

Halozyme Therapeutics

US · HALO #1276 by market cap Listed 1970
91.35 -1.69 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Above fair value
36.65 fair value ≈ 53.80 70.95
  • Implied fair-value range of 36.65-70.95, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +69.8% above the average-multiple fair value of 53.80.

Valuation each multiple against its own 5-year range

P/B ratio -213.67 Cheap vs history 0th percentile
5-year average 39.89 · #504 of 507 in Biotechnology
P/E ratio 25.91 Expensive vs history 79th percentile
5-year average 21.01 · forward 11.10 · #53 of 76 in Biotechnology
P/S ratio 6.55 In line with history 33rd percentile
5-year average 8.23 · forward 5.59 · #137 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Halozyme Therapeutics (HALO) 10.41B 22.84 -188.35 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value113.38 Economic moatWide UncertaintyHigh

Trading 24.1% below Morningstar's fair value estimate.

Fair value

Halozyme Therapeutics Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $113.38 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's solid growth bolsters our valuation estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 30.8% sits in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

Alternatively, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 1.0%, a core component of valuation, ranks in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's wide quantitative moat rating suggests a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Halozyme Therapeutics discussion 0 comments

Add a comment